Diligence memo · auto-generated · as of July 2, 2026
Bilayer Therapeutics, Inc.
Bilayer Therapeutics, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Bilayer Therapeutics, Inc. operates in Biotechnology, based in CAMBRIDGE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Bilayer Therapeutics, Inc. has raised $2.3M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.0M on 2021-04-19.
Most recent recorded round closed around 2023-08-03.
Valuation (modeled)modeled
Provath models Bilayer Therapeutics, Inc. at approximately $2.4M (range $216K–$8.2M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.17× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 27 months.
Last raise 2.9 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 6.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 30% of Biotechnology peers (4293 compared).
Modeled value ranks above 6% of those peers.
Closest niche peers: Mesentech Inc., Marlinspike Therapeutics, Inc., Microbial Machines, Inc., Pearl Diagnostics, Inc., Crossfire Medical Inc.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.